详细说明
- Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
- Endotoxin Level<0.10 EU per 1 μg of the protein by the LAL method.
- ActivityMeasured in a competitive binding assay. When human LDL is immobilized at 1 μg/mL (100 μL/well), Recombinant Human LDL R inhibits 50% binding of Biotinylated Recombinant Human LDL R (0.5 μg/mL) at the concentration range of 0.2-1.2 μg/mL.
- SourceHuman embryonic kidney cell, HEK293-derived Ala22-Arg788 (Asp193Ala), with a C-terminal 6-His tag
- Accession #
- N-terminal Sequence
AnalysisAla22 - Predicted Molecular Mass86 kDa
- SDS-PAGE120-140 kDa, reducing conditions
9177-LD | | |
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. | ||
Reconstitution Reconstitute at 100 μg/mL in PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Bioactivity | When Human LDL is immobilized at 1 μg/mL (100 μL/well),Recombinant Human LDL R (Catalog # 9177-LD) inhibits the binding between HumanLDL and Biotinylated Recombinant Human LDL R. The ED50 for this effect is0.2-1.2 μg/mL. |
beta -propeller structures (class B LDL repeats) in the extracellular domain (ECD) (1-7). A membrane-proximal Ser/Thr-rich region shows extensive O-linked glycosylation (4, 8). A cytoplasmic NPxY motif links the LDL R to clathrin pits for endocytosis, and binds to select adaptor proteins (1, 4, 8). The human LDL R ECD shares 78%, 76%, 81% and 82% aa sequence identity with mouse, rat, bovine, and porcine LDL R, respectively. LDL R is constitutively and widely expressed. Its class A LDL domains near the N-terminus bind apoB and apoE, the apolipoproteins of low- and very low-density lipoproteins (LDL and VLDL), respectively (1, 2, 4, 9). Hepatocyte LDL R is responsible for endocytosis and clearing of most plasma LDL cholesterol (2, 9). At the low pH of the endocytic vesicle, it dissociates, allowing degradation of LDL and recycling of LDL R to the cell surface (1, 4). Lack of LDL R expression or function causes familial hypercholesterolemia (FH) (4, 9, 10). The protease PCSK9 (proprotein convertase subtilisin/kexin type 9) can also cause increased plasma cholesterol by promoting LDL R degradation rather than recycling to the cell surface (10-12). Soluble forms of approximately 140 kDa and 28 kDa are reported to be released by phorbol esters or interferons, respectively (6, 7).
- References:
- Go, G.W. and A. Mani (2012) Yale J. Biol. Med. 85:19.
- Ren, G. et al. (2010) Proc. Natl. Acad. Sci. USA 107:1059.
- Bujo, H. and Y. Saito (2006) Arterioscler. Thromb. Vasc. Biol. 26:1246.
- Gent, J. and I. Braakman (2004) Cell. Mol. Life Sci. 61:2461.
- Yamamoto, T. et al. (1984) Cell 39:27.
- Begg, M.J. et al. (2004) Eur. J. Biochem. 271:524.
- Fischer, D.G. et al. (1993) Science 262:250.
- Stolt, P.C. and H.H. Bock (2006) Cell. Signal. 18:1560.
- Defesche, J.C. (2004) Semin. Vasc. Med. 4:5.
- De Castro-Oros, I. et al. (2010) Appl. Clin Genet. 3:53.
- Zhang, D.W. et al. (2008) Proc. Natl. Acad. Sci. USA 105:13045.
- Tavori, H. et al. (2013) Circulation 127:2403.
- Long Name:Low Density Lipoprotein Receptor
- Entrez Gene IDs:3949 (Human); 16835 (Mouse); 300438 (Rat)
- Alternate Names:FH; FHC; LDL R; LDL receptor; LDLCQ2; LDLR; low density lipoprotein receptor; low-density lipoprotein receptor class A domain-containing protein 3; low-density lipoprotein receptor